Antengene Appoints Dr. Haifei Gao as Vice President, Investor Relations and Capital Markets to Strengthen Market Engagement and Communicate Corporate Value

Shanghai and Hong Kong, PRC, November 2, 2026 -- Antengene Corporation Limited (**"Antengene"**, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced **the appointment of Dr. Haifei Gao as Vice President, Investor Relations and Capital Markets, with overall responsibility for the company's investor relations, capital markets engagement, and market capitalization management**.

Dr. Haifei Gao brings a robust academic and industrial foundation in innovative drug development, a background as a chief sell-side pharmaceutical analyst, and a proven track record in investor relations management at a publicly listed company. He possesses deep insight into the value drivers of cutting-edge biotechnologies and pipelines—including ADC, peptides, small molecules, and mRNA delivery—alongside demonstrated capabilities in industry research and the execution of capital markets strategies.

上海市长宁区中山西路 1065 号 SOHO 中山广场 B 座 1206-1209 室
Suite 1206-1209, Building B, SOHO Plaza, 1065 West Zhongshan Road, Shanghai 200051, China
Tel: (86) 021 3250 1095
Fax: (86) 021 3250 1062
www.antengene.com

Prior to joining Antengene, Dr. Gao served as Executive Director of Investor Relations at Everest Medicines, where he was tasked with establishing the company's IR framework, managing market capitalization, and overseeing engagement with global capital markets to ensure the effective articulation of the value embedded in the company's pipeline and corporate strategy. Previously, he served as Lead Pharmaceutical Analyst at Great Wall Securities, where he spearheaded in-depth research across the biopharmaceutical sector and managed a team dedicated to serving and cultivating relationships with leading institutional and non-institutional investors. Earlier in his career, Dr. Gao held R&D roles at WuXi AppTec and Everest Medicines, where he was engaged in drug discovery and process development across a wide range of modalities, including ADCs, peptides, and small molecules. Dr. Gao holds bachelor's and master's degrees in pharmacy from Peking University, as well as a Ph.D. in chemical biology from the Institut Curie / University of Paris. He subsequently completed postdoctoral research at the French National Centre for Scientific Research (CNRS) / University of Paris, focusing on mRNA delivery technologies including lipid nanoparticles (LNPs) and lipid-polymer hybrids (LPRs), as well as ADC drug development and the mechanisms of transmembrane drug transport.

Dr. Jay Mei, Antengene's Founder, Chairman, and CEO, commented, "We are pleased to welcome Dr. Haifei Gao to the Antengene leadership team. Dr. Gao is a cross-functional talent in the biopharmaceutical industry, bringing together expertise in R&D, industry research, and investor relations. As we continue to advance the development of our key programs, including ATG-022 (CLDN18.2 ADC), ATG-125 (anti-PD-L1/B7H3 ADC), and ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein), as well as the AnTenGager® TCE platform and the TriGager™ TCE platform, Dr. Gao will leverage his deep scientific insights to help the capital markets gain a clearer understanding of our pipeline data, technology platforms, and long-term strategy. He will play a pivotal role in articulating the value of our R&D efforts and advancing the shareholder interests."

Dr. Haifei Gao commented, "Antengene is a highly promising next-generation global biotechnology company driven by innovative R&D, and I am honored to join the company at this pivotal stage of its growth. I have strong confidence in the differentiated technology platforms and global pipeline strategy that Antengene has established. Leveraging my cross-functional experience in R&D, industry research, and investor relations, I look forward to building an effective bridge between the

company and the capital markets, clearly articulating pipeline milestones and long-term strategy to global investors, and helping the market fully recognize the company's intrinsic value."

About Antengene

Antengene Corporation Limited ("**Antengene**" , SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager® platform.

AnTenGager®, is Antengene's proprietary TCE 2.0 platform, featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological malignancies,

with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 35 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made

in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.